Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $1.04 per share. This compares to loss of $0.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -59.62%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $1.13 per share when it actually produced earnings of $1.44, delivering a surprise of 27.43%.Over the last four ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction o ...

Exhibit 99.1 Neurocrine Biosciences Reports First Quarter 2024 Financial Results INGREZZA (valbenazine) First Quarter Net Product Sales of $506 Million Representing 23% Year-Over- Year Growth ® INGREZZA SPRINKLE (valbenazine) Capsules Approved by the U.S. FDA ® Crinecerfont New Drug Applications for the Treatment of Congenital Adrenal Hyperplasia Submitted to the U.S. FDA Positive Phase 2 Top-Line Data for NBI-1065845, a Potential First-In-Class AMPA Positive Allosteric Modulator, in Adults with Major Depre ...

SAN DIEGO, April 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA® (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.1 INGREZZA SPRINKLE provides an alternative administration option for those who experience dysphagia or have difficulty swallowing. Like ...

Wall Street analysts forecast that Neurocrine Biosciences (NBIX) will report quarterly earnings of $1.04 per share in its upcoming release, pointing to a year-over-year increase of 231.7%. It is anticipated that revenues will amount to $512.21 million, exhibiting an increase of 21.8% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 3.8% to its current level. This demonstrates the covering analysts' collective reassessment of the ...

WHAT THE C@H?! provides a platform for the congenital adrenal hyperplasia (CAH) community to find educational information, share experiences and learn about current research. SAN DIEGO, April 24, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap in the need for helpful information about congenital adrenal hyperplasia (CAH) and acknowledges the frustrations and challenges experienced by the co ...

For the transition period from __________to__________ Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 33-0525145 (State or other jur ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) Q4 2023 Earnings Conference Call February 7, 2024 8:00 AM ET Company Participants Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Kyle Gano - Chief Business Development and Strategy Officer Todd Tushla - Vice President, Investor Relations Conference Call Participants Paul Matteis - Stifel Tazeen Ahmad - Bank of America Brian Skorney - Baird Phil Nadeau - T ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Kyle Gano - Chief Business Development and Strategy Officer Conference Call Participants Phil Nadeau - TD Cowen Chris Shibutani - Goldman Sachs Paul Matteis - Stifel Tazeen Ahmad - ...

Open-Label Treatment (one year) OpenLabel Extension* Participants randomized to placebo will receive crinecerfont during open-label treatment Objective Evaluate the efficacy, safety and tolerability of crinecerfont in adults with classic CAH Crinecerfont is investigational and not approved in any country *The duration of participation in the study is approximately 20 months for the core study and will be a variable amount of time per participant for the open-label extension CAHtalystTM Adult and Pediatric S ...